|
Palo Alto, CA, June 9, 2004 — Palo Alto, CA, June
9, 2004 — Telik, Inc. (Nasdaq: TELK) announced that company
management will present an corporate update at the Pacific Growth
Equities Life Sciences Conference on June 10, 2004 at 9:30 a.m.
Pacific time (12:30 p.m. Eastern time) at the Mark Hopkins Intercontinental
Hotel in San Francisco.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
cancer and other serious diseases. The company’s most advanced
drug development candidate is TELCYTA™, currently in Phase
3 registration trials in ovarian and non-small cell lung cancer.
Telik’s product candidates were discovered using its proprietary
drug discovery technology, TRAP, which enables the rapid and efficient
discovery of small molecule drug candidates. Additional information
is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2004
Press Releases2003
Press ReleasesEvents
|
